Literature DB >> 26807187

Increased matrix metalloproteinase-2 expression and reduced tissue factor pathway inhibitor-2 expression correlate with angiogenesis and early postoperative recurrence of pancreatic carcinoma.

Lu-Lu Zhai1, Yang Wu1, Da-Wei Huang1, Zhi-Gang Tang1.   

Abstract

Matrix metalloproteinase (MMP)-2 and tissue factor pathway inhibitor (TFPI)-2 are known to influence tumor angiogenesis and progression. This work aimed to describe the levels of MMP-2 and TFPI-2 expression associated with tumor angiogenesis and early postoperative recurrence in patients with pancreatic carcinoma. Expression of MMP-2 and TFPI-2 in carcinoma tissues and paracarcinomatous tissues was assayed by immunostaining. Expression of vascular endothelial growth factor (VEGF) and CD34 in tumor tissues was also assayed by immunostaining. The correlations of MMP-2 and TFPI-2 with VEGF, microvessel density (MVD), and early postoperative recurrence were analyzed. The results showed that MMP-2 expression was significantly increased (P < 0.05) and TFPI-2 expression was significantly decreased (P < 0.001) in carcinoma tissues compared with paracarcinomatous tissues. MMP-2 expression was positively correlated with VEGF (r = 0.594, P < 0.001) and MVD (r = 0.432, P < 0.001) in carcinoma tissues. TFPI-2 expression was negatively correlated with VEGF (r = -0.654, P < 0.001) and MVD (r = -0.360, P < 0.001) in carcinoma tissues. Multivariate logistic regression analysis showed that up-regulated MMP-2 and down-regulated TFPI-2 were independent predictors of early postoperative recurrence of pancreatic carcinoma. Receiver operating characteristic curve analysis showed that the combination of MMP-2 and TFPI-2 was a reliable predictive model of early recurrence. We conclude that increased MMP-2 expression and reduced TFPI-2 expression are closely linked to angiogenesis and early postoperative recurrence of pancreatic carcinoma. Immunohistochemical assay of MMP-2 and TFPI-2 may be useful for predicting early relapse of pancreatic carcinoma after surgery.

Entities:  

Keywords:  MMP-2; TFPI-2; angiogenesis; pancreatic carcinoma; recurrence

Year:  2015        PMID: 26807187      PMCID: PMC4697719     

Source DB:  PubMed          Journal:  Am J Transl Res            Impact factor:   4.060


  51 in total

1.  CD147, MMP-2, MMP-9 and MVD-CD34 are significant predictors of recurrence after liver transplantation in hepatocellular carcinoma patients.

Authors:  Qing Zhang; Xinguo Chen; Jun Zhou; Li Zhang; Qingchuan Zhao; Guangsheng Chen; Jing Xu; Feng Qian; Zhinan Chen
Journal:  Cancer Biol Ther       Date:  2006-07-30       Impact factor: 4.742

2.  Diagnostic utility of aberrant methylation of tissue factor pathway inhibitor 2 in pure pancreatic juice for pancreatic carcinoma.

Authors:  PeiHong Jiang; Hiroyuki Watanabe; Gensaku Okada; Koushiro Ohtsubo; Hisatsugu Mouri; Tomoya Tsuchiyama; Fan Yao; Norio Sawabu
Journal:  Cancer Sci       Date:  2006-09-05       Impact factor: 6.716

3.  Survival in population-based pancreatic cancer patients: San Francisco Bay area, 1995-1999.

Authors:  Zhihong Gong; Elizabeth A Holly; Paige M Bracci
Journal:  Am J Epidemiol       Date:  2011-11-01       Impact factor: 4.897

4.  Differential expression of matrix metalloproteinase (MMP)-2, MMP-9, and membrane type 1-MMP in hepatocellular and pancreatic adenocarcinoma: implications for tumor progression and clinical prognosis.

Authors:  M Määttä; Y Soini; A Liakka; H Autio-Harmainen
Journal:  Clin Cancer Res       Date:  2000-07       Impact factor: 12.531

5.  Rac1/Pak1/p38/MMP-2 Axis Regulates Angiogenesis in Ovarian Cancer.

Authors:  Vianey Gonzalez-Villasana; Enrique Fuentes-Mattei; Cristina Ivan; Heather J Dalton; Cristian Rodriguez-Aguayo; Ricardo J Fernandez-de Thomas; Burcu Aslan; Paloma Del C Monroig; Guermarie Velazquez-Torres; Rebecca A Previs; Sunila Pradeep; Nermin Kahraman; Huamin Wang; Pinar Kanlikilicer; Bulent Ozpolat; George Calin; Anil K Sood; Gabriel Lopez-Berestein
Journal:  Clin Cancer Res       Date:  2015-01-16       Impact factor: 12.531

6.  Subcellular localization of PP5/TFPI-2 in human placenta: a possible role of PP5/TFPI-2 as an anti-coagulant on the surface of syncytiotrophoblasts.

Authors:  K Udagawa; H Yasumitsu; M Esaki; H Sawada; Y Nagashima; I Aoki; M Jin; E Miyagi; T Nakazawa; F Hirahara; K Miyazaki; Y Miyagi
Journal:  Placenta       Date:  2002 Feb-Mar       Impact factor: 3.481

7.  Tissue factor pathway inhibitor-2 is a novel inhibitor of matrix metalloproteinases with implications for atherosclerosis.

Authors:  M P Herman; G K Sukhova; W Kisiel; D Foster; M R Kehry; P Libby; U Schönbeck
Journal:  J Clin Invest       Date:  2001-05       Impact factor: 14.808

8.  Correlation and prognostic significance of MMP-2 and TFPI-2 differential expression in pancreatic carcinoma.

Authors:  Lu-Lu Zhai; Chong-Yang Cai; Yang Wu; Zhi-Gang Tang
Journal:  Int J Clin Exp Pathol       Date:  2015-01-01

9.  The role of MMP-2 and MMP-9 as prognostic markers in the early stages of tongue squamous cell carcinoma.

Authors:  Manikkath Aparna; Lakshmi Rao; Vijayanarayana Kunhikatta; Raghu Radhakrishnan
Journal:  J Oral Pathol Med       Date:  2014-09-12       Impact factor: 4.253

10.  Reduced expression of tissue factor pathway inhibitor-2 contributes to apoptosis and angiogenesis in cervical cancer.

Authors:  Qiao Zhang; Yao Zhang; Shi Z Wang; Ning Wang; Wei G Jiang; Yao H Ji; Shu L Zhang
Journal:  J Exp Clin Cancer Res       Date:  2012-01-02
View more
  9 in total

1.  Overexpression of tissue factor pathway inhibitor 2 attenuates trophoblast proliferation and invasion in preeclampsia.

Authors:  Lili Zheng; Jing Huang; Yuan Su; Fang Wang; Hongfang Kong; Hong Xin
Journal:  Hum Cell       Date:  2020-03-04       Impact factor: 4.174

2.  Defining and Predicting Early Recurrence in 957 Patients With Resected Pancreatic Ductal Adenocarcinoma.

Authors:  Vincent P Groot; Georgios Gemenetzis; Alex B Blair; Roberto J Rivero-Soto; Jun Yu; Ammar A Javed; Richard A Burkhart; Inne H M Borel Rinkes; I Quintus Molenaar; John L Cameron; Matthew J Weiss; Christopher L Wolfgang; Jin He
Journal:  Ann Surg       Date:  2018-03-23       Impact factor: 12.969

3.  A double suicide gene system driven by vascular endothelial growth factor promoter selectively kills human hepatocellular carcinoma cells.

Authors:  Kai Wu; Liucheng Yang; Zonghai Huang; Haijun Zhao; Jianjun Wang; Shuai Xu
Journal:  Oncol Lett       Date:  2016-03-22       Impact factor: 2.967

4.  Defining and Predicting Early Recurrence in 957 Patients With Resected Pancreatic Ductal Adenocarcinoma.

Authors:  Vincent P Groot; Georgios Gemenetzis; Alex B Blair; Roberto J Rivero-Soto; Jun Yu; Ammar A Javed; Richard A Burkhart; Inne H M Borel Rinkes; I Quintus Molenaar; John L Cameron; Matthew J Weiss; Christopher L Wolfgang; Jin He
Journal:  Ann Surg       Date:  2019-06       Impact factor: 13.787

5.  CD155 expression and its correlation with clinicopathologic characteristics, angiogenesis, and prognosis in human cholangiocarcinoma.

Authors:  Da-Wei Huang; Mei Huang; Xian-Sheng Lin; Qiang Huang
Journal:  Onco Targets Ther       Date:  2017-07-31       Impact factor: 4.147

6.  Predictive risk factors for early recurrence in patients with localized pancreatic ductal adenocarcinoma who underwent curative-intent resection after preoperative chemoradiotherapy.

Authors:  Yasuhiro Murata; Toru Ogura; Aoi Hayasaki; Kazuyuki Gyoten; Takahiro Ito; Yusuke Iizawa; Takehiro Fujii; Akihiro Tanemura; Naohisa Kuriyama; Masashi Kishiwada; Hiroyuki Sakurai; Shugo Mizuno
Journal:  PLoS One       Date:  2022-04-04       Impact factor: 3.240

7.  Early recurrence detected by 18F-FDG PET/CT in patients with resected pancreatic ductal adenocarcinoma.

Authors:  Li Wang; Ping Dong; Weiguo Wang; Mao Li; Weiming Hu; Xubao Liu; Bole Tian
Journal:  Medicine (Baltimore)       Date:  2020-03       Impact factor: 1.817

8.  MicroRNA-23a acts as an oncogene in pancreatic carcinoma by targeting TFPI-2.

Authors:  Wei Wang; Jin-Zhuo Ning; Zhi-Gang Tang; Ying He; Li-Chao Yao; Lin Ye; Lun Wu
Journal:  Exp Ther Med       Date:  2020-09-04       Impact factor: 2.447

9.  Development of a Biomarker-Based Scoring System Predicting Early Recurrence of Resectable Pancreatic Duct Adenocarcinoma.

Authors:  Keinosuke Ishido; Norihisa Kimura; Taiichi Wakiya; Hayato Nagase; Yutaro Hara; Taishu Kanda; Hiroaki Fujita; Kenichi Hakamada
Journal:  Ann Surg Oncol       Date:  2021-10-04       Impact factor: 5.344

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.